KR Rai, P Jain - American journal of hematology, 2016 - Wiley Online Library
The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since the time clinical staging was introduced in clinical practice in 1975. Over the years, the …
WG Wierda, JC Byrd, JS Abramson, SF Bilgrami… - Journal of the National …, 2020 - jnccn.org
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone …
M Mikulska, S Lanini, C Gudiol, L Drgona… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
JML Casan, J Wong, MJ Northcott… - Human vaccines & …, 2018 - Taylor & Francis
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a …
The use of targeted biologic therapies for hematological malignancies has greatly expanded in recent years. These agents act upon specific molecular pathways in order to target …
Y Kikushige - Journal of clinical and experimental hematopathology, 2020 - jstage.jst.go.jp
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries and is characterized by the clonal expansion of mature CD5+ B cells. There have …
A Haslam, D Herrera-Perez, J Gill… - JAMA network open, 2020 - jamanetwork.com
Importance Quality of life (QoL) is an important consideration in cancer medicine, especially because drugs are becoming more costly and may only result in modest gains in overall …
JP Sharman, DM Brander, AR Mato, N Ghosh… - The Lancet …, 2021 - thelancet.com
Background Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this study was to …
L Iovino, M Shadman - Current Treatment Options in Oncology, 2020 - Springer
Opinion statement Treatment landscape of chronic lymphocytic leukemia (CLL) has changed since 2014 after the introduction of inhibitors of B-cell receptor signaling pathway …